• Antibiotics: an international pandemic

    Professor Jasmohan Bajaj talks about the overuse and misuse of antibiotics and how this will cause an international pandemic, if the "reset-button" to deescalate the use of antibiotics is not pressed soon.

  • Ulcerative Colitis: Reducing the burden of disease

    Professor Subrata Ghosh summarises the key findings of the ICONIC-study, which is the largest ongoing observational study on the burden of adult ulcerative colitis in patients under routine care. It comprises 1.816 enrolled patients in 33 countries throughout the globe.

  • CD treatment goals are best achieved through early, sufficient treatment

    Crohn’s disease (CD) is a progressive disorder and the achievement of mucosal healing lowers the risk of necessary surgery, according to Julián Panés (Spain).

  • Vedolizumab provides early symptomatic improvement in UC

    As early as week 2, patient-reported symptomatic improvements were achieved among UC patients treated with vedolizumab – including a combined reduction in defecation frequency and rectal blood loss. These findings underline the fast action of vedolizumab in treating UC, particularly when it is used as a first-line biological therapy.

  • Early treatment with vedolizumab for UC is most effective

    During the word of welcome given at the satellite symposium 'Rapid Action and Lasting Remission - Focus on Disease Progression in Ulcerative Colitis', William Sandborn came directly to the point: the sufficient treatment of UC is essential. In 50% of the patients suffering from the UC, the disease takes an adverse course.

  • Bridging strategy with calcineurin inhibitors and vedolizumab prevents need for colectomy

    A bridging strategy in which a calcineurin inhibitor and vedolizumab are combined seems to be effective in patients with active steroid-refractory ulcerative colitis. Such a strategy could be considered for patients with acute, severe UC and nonsevere UC that are resistant to conventional therapy, including anti-tumour necrosis factor (anti-TNF).

  • Therapy Update Colitis ulcerosa

    Professor Pierre Michetti summarizes new approaches in the treatment of ulcerative colitis.

  • Surgical options for severe Colitis ulcerosa patients

    In our interview, Professor Janindra Warusavitarne talks about minimally invasive surgical intervention for patients with severe ulcerative colitis.

  • Colitis ulcerosa: risks of discontinuing treatment

    Professor Chris Probert talks about the current state of research and presents results of a recent study on clinical efficacy and patient safety of Golimumanb for induction and maintenance in patients with moderate to severe colitis ulcerosa.

  • Mucosal healing in ulcerative colitis

    Dr. Peter Bossuyt summarizes his scientific talk about results of the Real Life - BE SMART study. He primarily speaks about an early mucosal healing in connection with the TNF-α inhibitor Golimumab.

  • New developments in IBD research

    From biologicals to microbiome: Dr. Johan Burisch informs about the most exciting developments in research and treatment of chronic inflammatory bowel disease (IBD).